Boston Biomedical, Inc. is a fully integrated oncology drug research and development company headquartered in Cambridge, Massachusetts. They have a track record of advancing multiple compounds and clinical programs in areas such as drug discovery, preclinical development, global clinical trials, and commercialization. The company is focused on developing innovative treatments for cancer by leveraging their innovation-driven culture, scientific leadership, and drug development expertise. Boston Biomedical, Inc. is indirectly owned by Sumitomo Dainippon Pharma Co., Ltd., a Japanese pharmaceutical company, which acquired Tolero Pharmaceuticals in 2017 to expand its global oncology and hematology portfolios. Together, these companies collaborate to expedite drug discovery, development, and commercialization, with the goal of significantly improving patient outcomes.